Dose optimization and safety
anaemia, decreased white blood cell count, DLTs, febrile neutropenia, hypertension, TRAEs
ANAEMIA, HYPERTENSION, FEBRILE NEUTROPENIA
During dose escalation, 7 dose combinations, up to fuzuloparib 100 mg bid plus apatinib 500 mg qd, were evaluated. Two of 27 patients in the dose-escalation cohort had DLTs in the first cycle. At the dose level of fuzuloparib 100 mg plus apatinib 250 mg, 1 patient experienced febrile neutropenia and grade 4 decreased white blood cell count; at fuzuloparib 100 mg plus apatinib 375 mg, 1 patient experienced grade 4 decreased platelet count. The maximum tolerated dose (MTD) was not reached.Overall, 19 (36.5%) of 52 enrolled patients had at least one grade ≥ 3 TRAE, with the most common being hypertension (10 [19.2%] patients), anaemia (7 [13.5%]), and decreased platelet count (3 [5.8%]; Table TRAEs occurring in ≥ 10% of patientsData are n (%). All grade ≥ 3 TRAEs occurring in ≥ 2% of patients are listed. 